Trial Profile
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 14 Oct 2013 New trial record